The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk...The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported ini- tial quality of life （QoL） results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.展开更多
Prostate cancer remains a leading cause of cancer death in Europe andthe United States and is an emerging problem in Asia despite significant improvements in available treatments over the last few decades. Androgen de...Prostate cancer remains a leading cause of cancer death in Europe andthe United States and is an emerging problem in Asia despite significant improvements in available treatments over the last few decades. Androgen deprivation therapy （ADT） has been the core treatment of advance-staged disease since the discovery of prostate cancer＇s androgen dependence in 1941 by Huggins et al. Options for initial medical treatment include gonadotropin-releasing hormone analogues such as leuprolide （LHRH agonist） and degarelix （LHRH antagonist） and androgen receptor （AR） binding agents such as bicalutamide. Although most patients will initially respond to either surgical or medical castration, there is almost always progression to castration-resistant prostate cancer （CRPC） necessitating treatment with more novel agents. However, even drugs such as abiraterone and enzalutamide, two next-generation agents used commonly in metastatic CRPC, have failed to demonstrate persistent efficacy in most patients.展开更多
文摘The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported ini- tial quality of life （QoL） results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.
文摘Prostate cancer remains a leading cause of cancer death in Europe andthe United States and is an emerging problem in Asia despite significant improvements in available treatments over the last few decades. Androgen deprivation therapy （ADT） has been the core treatment of advance-staged disease since the discovery of prostate cancer＇s androgen dependence in 1941 by Huggins et al. Options for initial medical treatment include gonadotropin-releasing hormone analogues such as leuprolide （LHRH agonist） and degarelix （LHRH antagonist） and androgen receptor （AR） binding agents such as bicalutamide. Although most patients will initially respond to either surgical or medical castration, there is almost always progression to castration-resistant prostate cancer （CRPC） necessitating treatment with more novel agents. However, even drugs such as abiraterone and enzalutamide, two next-generation agents used commonly in metastatic CRPC, have failed to demonstrate persistent efficacy in most patients.
